SuPAR and FSGS: The gap between bench and bedside

Transplantation

Volumn 96, Issue 4, 2013, Pages 368-369

  Naesens, Maarten ^a,b   Meijers, Björn ^a,b   Sprangers, Ben ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MOLECULAR WEIGHT; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84883452377     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829e6d40     Document Type: Note

References (19)

1. Huttunen R, Syrjanen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: A prospective cohort study. J Intern Med 2011; 270: 32.
2. Kjellman A, Akre O, Gustafsson O, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening. J Intern Med 2011; 269: 299.
3. Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: A prospective observational study. Crit Care 2012; 16: R130.
4. Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review. Intensive Care Med 2012; 38: 1418.
5. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296.
6. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952.
7. Reiser J, Wei C, Tumlin J. Soluble urokinase receptor and focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2012; 21: 428.
8. Huang J, Liu G, Zhang YM et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013; doi: 10.1038/ki.2013.55 [Epub ahead of print].
9. Maas RJ, Wetzels JF, Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 2012; 81: 1043.
10. Bock ME, Price HE, Gallon L, et al. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: A single-center report. Clin J Am Soc Nephrol 2013 [Epub ahead of print].
11. Trachtman H, Gipson DS, Kaskel F, et al. Regarding Maas's editorial letter on serum suPAR levels. Kidney Int 2012; 82: 492.
12. Palacios CRF, Lieske JC,Wadei HM, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013; 96: 394.
13. Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366: 1648.
14. Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15: R63.
15. Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23: 2051.
16. Pawlak K, Ulazka B, Mysliwiec M, et al. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: A new link between angiogenesis and hyperfibrinolysis? Transl Res 2012; 160: 346.
17. Yilmaz G, Koksal I, Karahan SC, et al. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 2011; 44: 1227.
18. Sier CF, Sidenius N, Mariani A, et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999; 79: 717.
19. Sorio C, Mafficini A, Furlan F, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011; 11: 448.